• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

    41.35 +0.56 (+1.37%)
    Streaming Delayed Price Updated: 11:30 AM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 208,157
    Open 41.27
    Bid (Size) 41.25 (200)
    Ask (Size) 41.53 (100)
    Prev. Close 40.79
    Today's Range 40.75 - 42.50
    52wk Range 13.62 - 44.28
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? ↗
    This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid a year of exceptional stock appreciation. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +47.1%
    +47.1%
    1 Month
    +7.2%
    +7.2%
    3 Month
    +16.4%
    +16.4%
    6 Month
    +49.0%
    +49.0%
    1 Year
    +194.5%
    +194.5%

    More News

    Read More
    Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines ↗
    Via Chartmill
    News headline image
    Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
    Via Benzinga
    News headline image
    Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Rapport Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Rapport Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Rapport Therapeutics, Inc. - Common Stock trade on?
    Rapport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rapport Therapeutics, Inc. - Common Stock?
    The ticker symbol for Rapport Therapeutics, Inc. - Common Stock is RAPP on the Nasdaq Stock Market
    What is the current price of Rapport Therapeutics, Inc. - Common Stock?
    The current price of Rapport Therapeutics, Inc. - Common Stock is 41.35
    When was Rapport Therapeutics, Inc. - Common Stock last traded?
    The last trade of Rapport Therapeutics, Inc. - Common Stock was at 08/04/26 11:30 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.